Octreotide Functionalized Nano-Contrast Agent for Targeted Magnetic Resonance Imaging

Area of Science:

• Nanotechnology
• Polymer Chemistry
• Biomedical Imaging

Background:

• Development of advanced nanocontrast agents for Magnetic Resonance Imaging (MRI) is crucial for improved diagnostic accuracy.
• Gadolinium-based contrast agents (GBCAs) are widely used but have limitations.
• Targeted delivery systems can enhance imaging specificity and reduce off-target effects.

Purpose of the Study:

• To synthesize novel branched block copolymer nanoparticles for targeted MRI applications.
• To incorporate gadolinium (Gd3+) chelators and somatostatin receptor-targeting peptides into the nanoparticle structure.
• To evaluate the MRI performance and tumor-targeting capabilities of these nanocontrast agents.

Main Methods:

• Synthesis of branched block copolymer nanoparticles using Reversible Addition-Fragmentation chain Transfer (RAFT) polymerization.
• Incorporation of 1,4,7,10-tetraazacyclododecane-N,N,'N,″N,‴-tetraacetic acid (DO3A) macrocycles and octreotide peptides.
• Chelation with Gd3+ and evaluation of relaxivity, in vitro binding affinity to somatostatin receptor type 2 (SSTR2), and in vivo tumor targeting in xenograft mouse models.

Main Results:

• Synthesized nanoparticles exhibited an r1 relaxivity of 8.3 mM−1 s−1, three times higher than commercial GBCAs.
• Nanoparticles demonstrated a 5-fold greater affinity for SSTR2 (Ki = 77 pM) compared to somatostatin (Ki = 0.385 nM).
• Successful in vivo tumor imaging was observed in SSTR2-positive (AR42J) xenografts, with minimal uptake in SSTR2-negative (A549) xenografts.

Conclusions:

• Branched block copolymer nanoparticles functionalized with DO3A and octreotide serve as effective MRI nanocontrast agents.
• The developed system offers superior relaxivity and targeted binding for enhanced molecular imaging of SSTR2-expressing tumors.
• This targeted nanomedicine approach holds promise for improved cancer diagnostics.